Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2025-05-19 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la p
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a specific corporate event: receiving a Chinese patent for Masitinib in the treatment of COVID-19. This type of announcement, detailing a specific development (like intellectual property news, clinical trial updates, or partnership agreements) released via a press release format, is typically classified as a general Regulatory Filing (RNS) if no other specific category fits perfectly. It is not a formal statutory report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). Since it is a specific, non-standard announcement, RNS is the most appropriate fallback category for general regulatory/corporate news releases.
2025-05-19 French
AB Science annonce aujourd'hui une nouvelle publication dans la revue scientifique PLOS One, montrant l’effet neuroprotecteur prometteur du masitinib
Investor Presentation Classification · 1% confidence The document is a press release from AB Science SA, dated May 15, 2025, announcing the publication of a scientific study in the journal *PLOS One* regarding the neuroprotective effects of Masitinib. It details key findings, quotes the chairman of the scientific committee, and provides background information on the biomarker NfL and the company. This format—an announcement of scientific or clinical progress, often referencing a publication or trial result—is characteristic of an Investor Presentation (IP) or a general press release detailing research findings. Since it is a detailed announcement of research results and potential therapeutic applications, and not a formal regulatory filing like a 10-K or a short notice of a report release (RPA/RNS), 'Investor Presentation' (IP) is the most fitting category for disseminating this type of strategic and scientific update to investors, even though it is structured as a press release. It is more detailed than a standard Earnings Release (ER) and focuses on R&D progress.
2025-05-15 French
AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
Investor Presentation Classification · 1% confidence The document is a press release from AB Science announcing the publication of research findings regarding their drug, masitinib, in the scientific journal *PLOS One*. It details preclinical results related to neuroprotection and inflammation biomarkers (NfL). This type of announcement, which communicates scientific progress, clinical trial updates, or research findings to the public and investors, is typically classified as an Investor Presentation (IP) if it contains detailed slides/data, or sometimes as an Earnings Release (ER) if it's a brief summary accompanying financial results. However, since this document is a detailed scientific/research update presented as a press release, and it is not a formal regulatory filing (like 10-K or IR), nor is it a transcript (CT) or a management discussion (MDA), the most appropriate category among the provided options for detailed investor-focused scientific updates that aren't formal financial reports is Investor Presentation (IP). It functions as a detailed update on the science supporting the drug pipeline, which is crucial for investor assessment, even though it's not a slide deck itself. Given the options, IP is the best fit for a detailed scientific/pipeline update press release.
2025-05-15 English
Rapport Financier Annuel 2024
Annual Report (ESEF) Classification · 1% confidence FY 2024
2025-05-14 French
AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2024 et présente un point sur ses activités
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" and explicitly states it presents the "RÉSULTATS FINANCIERS ANNUELS AU 31 DECEMBRE 2024" (Annual Financial Results as of December 31, 2024). It includes key financial figures (operational deficit, cash position) and extensive updates on clinical development programs (Masitinib, AB8939). This structure—a press release detailing annual financial performance and operational highlights—is characteristic of an Earnings Release (ER). Although it covers the full year (implying annual data), it is presented as a press release summarizing results, not the comprehensive 10-K filing itself. Given the focus on financial results announcement, ER is the most appropriate code. The document length is substantial (33,600 chars), suggesting it contains more than just a brief announcement, but its format is that of a press release summarizing results, which aligns best with ER. FY 2024
2025-05-12 French
AB Science reports its revenues for the year 2024 and provides an update on its activities
Earnings Release Classification · 1% confidence The document is titled "AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD" and includes a section titled "CONSOLIDATED FINANCIAL INFORMATION FOR THE YEAR 2024". It details operating deficit, cash position, revenue, and operating expenses for the full year 2024, comparing them to 2023. This structure, focusing on full-year financial performance and key operational updates, strongly indicates an Annual Report or a document closely related to it. However, the format is a 'PRESS RELEASE' and it presents summarized financial data alongside extensive clinical development updates. Since it covers the full fiscal year (ending December 31, 2024) and provides detailed financial figures, it is most closely aligned with the content of an Annual Report (10-K). Given the context of a press release summarizing the year-end results, it is often the precursor or a summary of the full 10-K filing. Since it contains comprehensive year-end financial data, it is classified as an Annual Report (10-K) rather than just an Earnings Release (ER) which is typically quarterly, or a Report Publication Announcement (RPA) because it contains substantial content, not just a notice of publication. The length (over 30k characters) also supports it being a comprehensive report summary. FY 2024
2025-05-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.